ScholarIQanswers from OpenAlex & ORCID
Ravi K. Amaravadi
ResearcherPublications, citations & collaboration network
Ravi K. Amaravadi is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does Ravi K. Amaravadi have?
ScholarIQindexed works
Ravi K. Amaravadi has 580 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Ravi K. Amaravadi have?
ScholarIQcitation count
Ravi K. Amaravadi has 41,388 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of Ravi K. Amaravadi?
ScholarIQh-index
Ravi K. Amaravadi has an h-index of 83 in OpenAlex.
What is the i10-index of Ravi K. Amaravadi?
ScholarIQi10-index
Ravi K. Amaravadi has an i10-index of 160 in OpenAlex.
What is the ORCID of Ravi K. Amaravadi?
ScholarIQorcid
The ORCID for Ravi K. Amaravadi is on the source record.
What is the OpenAlex record for Ravi K. Amaravadi?
ScholarIQopenalex
The OpenAlex for Ravi K. Amaravadi is on the source record.
What are the most-cited papers on Ravi K. Amaravadi?
ScholarIQmost cited works
Guidelines for the use and interpretation of assays for monitoring autophagy
Daniel J. Klionsky, Fábio Camargo Abdalla, Hagai Abeliovich, Robert T. Abraham, Abraham Acevedo‐Arozena, Khosrow Adeli, Lotta Agholme, Maria Agnello, Patrizia Agostinis, Julio A. Aguirre‐Ghiso, Hyung Jun Ahn, Ouardia Aït-Mohamed, Slimane Ait‐Si‐Ali, Takahiko Akematsu, Shizuo Akira, Hesham M. Al‐Younes, Munir A. Al‐Zeer, Matthew L. Albert, Roger L. Albin, Javier Alegre‐Abarrategui, Maria Francesca Aleo, Mehrdad Alirezaei, Alexandru Almasan, Maylin Almonte‐Becerril, Atsuo Amano, Ravi K. Amaravadi, Shoba Amarnath, Amal O. Amer, Nathalie Andrieu‐Abadie, Vellareddy Anantharam, David K. Ann, Shailendra Anoopkumar‐Dukie, Hiroshi Aoki, Nadezda Apostolova, Giuseppe Arancia, John P. Aris, Katsuhiko Asanuma, Nana Asare, Hisashi Ashida, Valerie Askanas, David S. Askew, Patrick Auberger, Misuzu Baba, Steven K. Backues, Eric H. Baehrecke, Ben A. Bahr, Xue-Yuan Bai, Yannick Bailly, Robert A. Baiocchi, Giulia Baldini, Walter Balduini, Andrea Ballabio, Bruce A. Bamber, Edward T. W. Bampton, Gábor Juhász, Clinton R. Bartholomew, Diane C. Bassham, Robert C. Bast, Henri Batoko, Boon-Huat Bay, Isabelle Beau, Daniel M. Béchet, Thomas J. Begley, Christian Behl, Christian Behrends, Soumeya Bekri, Bryan H. Bellaire, Linda J. Bendall, Luca Benetti, Laura Berliocchi, Henri Bernardi, Francesca Bernassola, Sébastien Besteiro, Ingrid Bhatia-Kissova, Xiaoning Bi, Martine Biard-Piechaczyk, Janice S. Blum, Lawrence Boise, Paolo Bonaldo, David L. Boone, Beat Bornhäuser, Karina Ramalho Bortoluci, Ioannis Bossis, Frédéric Bost, Jean‐Pierre Bourquin, Patricia Boya, Michaël Boyer‐Guittaut, Peter V. Bozhkov, Nathan Brady, Claudio Brancolini, Andreas Brech, Jay E. Brenman, Ana Brennand, Emery Bresnick, Patrick Brest, Dave Bridges, Molly L. Bristol, Paul S. Brookes, Eric J. Brown, John H. Brumell
Combined MTOR and autophagy inhibition
Reshma Rangwala, Yunyoung C Chang, Janice Hu, Kenneth M. Algazy, Tracey L. Evans, Leslie A. Fecher, Lynn M. Schuchter, Drew A. Torigian, Jeffrey T Panosian, Andrea B. Troxel, Kay-See Tan, Daniel F. Heitjan, Angela DeMichele, David J. Vaughn, Maryann Redlinger, Abass Alavi, Jonathon Kaiser, Laura Pontiggia, Lisa E. Davis, Peter J. O’Dwyer, Ravi K. Amaravadi
Phase I trial of hydroxychloroquine with dose-intense temozolomide in patients with advanced solid tumors and melanoma
Reshma Rangwala, Robert D. Leone, Yunyoung C Chang, Leslie A. Fecher, Lynn M. Schuchter, Amy Kramer, Kay-See Tan, Daniel F. Heitjan, Glenda Rodgers, Maryann Gallagher, Shengfu Piao, Andrea B. Troxel, Tracey L. Evans, Angela DeMichele, Katherine L. Nathanson, Peter J. O’Dwyer, Jonathon Kaiser, Laura Pontiggia, Lisa E. Davis, Ravi K. Amaravadi